Uppsala, Sweden

Bo Nilsson

This inventor holds 15 USPTO granted patents and 6 published patent applications and 4 EPO patents, primarily in Biotechnology Applications. Top assignees: Tx Medic Ab, Allvivo, Inc., Astrazeneca Ab. Active years: 1990-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bo Nilsson. Retrieved from https://idiyas.com/inventor/bo-nilsson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 15 

% Patents Active = 66.7

 

Average Co-Inventor Count = 2.1

ph-index = 3

Forward Citations = 91(Granted Patents)


Location History:

  • Graso, 71 Oregrund, SE (1990)
  • 71 Oregrund, SE (1991)
  • 71 Oregrung, SE (2000)
  • Uppsala, SE (2006 - 2019)

Company Filing History:


Years Active: 1990-2019

Loading Chart...
Loading Chart...
Areas of Expertise:
Dextran Sulfate
Pulmonary Uptake
Graft-Rejection
Bioactive Compound
Transplantation Surgery
Bioartificial Implant
Elutable Coating
Type 1 Diabetes
Ultrasonic Transducer
Manufacturing Control
Plastic Material Regulation
15 patents (USPTO):Explore Patents

Title: Bo Nilsson: Innovator in Therapeutic Cell Transplantation

Introduction

Bo Nilsson is a prominent inventor based in Uppsala, Sweden. He has made significant contributions to the field of therapeutic cell transplantation, holding a total of 15 patents. His innovative work focuses on improving the efficacy and safety of cell therapies for human patients.

Latest Patents

Among his latest patents is a composition that utilizes dextran sulfate in a graft intended for transplantation. This composition comprises an injection solution that includes an isolated therapeutic cell transplant, which is beneficial for human patients. The dextran sulfate used in this context has an average molecular weight of less than 20,000 Da. Another notable patent addresses methods for reducing pulmonary uptake of intravenously injected cells. In this patent, dextran sulfate is employed to minimize the pulmonary uptake of these cells, achieving levels comparable to intra-arterial injection without the associated risks and side effects. This innovation can be particularly useful in treating metastatic cancer by combining dextran sulfate with tumor-infiltrating T-lymphocytes.

Career Highlights

Bo Nilsson has worked with various companies throughout his career, including Tx Medic AB. His work has been instrumental in advancing therapeutic techniques and improving patient outcomes in the field of cell transplantation.

Collaborations

Throughout his career, Bo has collaborated with notable individuals such as Olle Korsgren and Jonas Andersson. These collaborations have contributed to the development of innovative solutions in therapeutic cell applications.

Conclusion

Bo Nilsson's contributions to the field of therapeutic cell transplantation highlight his role as a leading inventor. His patents and collaborations reflect a commitment to advancing medical science and improving treatment options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…